Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
- Primary Children's Hospital — Salt Lake City, Utah
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Industry
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Utah: - Intermountain Medical Center ( Site 0182) — Murray, Utah
- Intermountain Healthcare - St. George ( Site 0203) — St. George, Utah
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Utah: - Primary Children's Hospital — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
- Intermountain Healthcare — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia …
Sponsor: Tanja Andrea Gruber
NCT ID: NCT05848687
Sites in Utah: - University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Utah: - Intermountain - Primary Children's Hospital ( Site 1014) — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.
Sponsor: T. John Winhusen, PhD
NCT ID: NCT06651177
Sites in Utah: - University of Utah — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to character…
Sponsor: Debiopharm International SA
NCT ID: NCT05765812
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) t…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT06238648
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated lymphoma,…
Sponsor: Estrella Immunopharma, Inc.
NCT ID: NCT06343311
Sites in Utah: - Intermountain Health, Canyons Region, LDS Hospital — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unr…
Sponsor: Recursion Pharmaceuticals Inc.
NCT ID: NCT06678659
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 2 Recruiting Academic/Other
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome that has come back (recurrent) or does not respond to treatment (refractory). Richter's synd…
Sponsor: Aseel Alsouqi
NCT ID: NCT05873712
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
Sponsor: University of Utah
NCT ID: NCT06390956
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refracto…
Sponsor: University of Utah
NCT ID: NCT06788964
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect again…
Sponsor: University of Utah
NCT ID: NCT05183854
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT04830137
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Academic/Other
The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCN…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07082868
Sites in Utah: - University of Utah (Data Collection Only) — Salt Lake City, Utah
Phase 1 Recruiting Industry
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic ly…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05091424
Sites in Utah: - Huntsman Cancer Institute at The University of Utah — Salt Lake City, Utah